New York, August 03, 2018: Market
Research Engine has published a new report titled as “Blood Screening Market By Technology Analysis (Nucleic Acid Test
(NAT), Enzyme-linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot
Assay, Next-generation Sequencing (NGS)); By End User Analysis (Blood Banks,
Hospitals); By Product/Services Analysis (Reagents & Kits, Enzymes and
Polymerases, Standards and Controls, Probes and Primers, Buffers, Nucleotides,
and Solutions, Labeling and Detection Reagents, Immunosorbents, Controls,
Conjugates, Substrates, Sample Diluents and Wash Solutions, Instruments,
Software and Services)”.
The Blood Screening Market is expected to exceed more than US$ 2.80
Billion by 2021 at a CAGR of 9.7% in the given forecast period.
Browse Full Report: https://www.marketresearchengine.com/blood-screening-market
Blood is a living tissue
made up of fluid, with various cells and proteins suspended in it. It is a
coursing liquid, containing red platelets, white platelets, and platelets. It
gives oxygen and food to the body cells through vessels, conductors, and veins.
It additionally expels metabolic waste and carbon dioxide from the body. A
blood screening is a therapeutic procedure in which blood is analyzed for a
particular illness or condition. It screens ailments and prevent medicinal
issues and a combination of various conditions, for instance, maladies and
danger. Blood screening is a medicinal procedure in which given blood is mostly
tried for HIV1, HIV2, HBV, HCV, jungle fever, syphilis, and different
irresistible ailments. Given blood is screened for these irresistible illnesses
to lessen the danger of transfusion-transmitted contaminations (TTIs). The
worldwide blood screening market comprises of different advances and items and
administrations which are utilized as a part of blood donation centers and
doctor's facilities for the screening of different TTIs.
The major
driving factors of Blood Screening
Market are as follows:
- Growing demand for donated blood and the donors.
- Conducting number of blood donation camps.
- Increasing safety and knowledge of donated blood.
- Economic price and acceptance of NAT for blood screening.
The
restraining factors of Blood Screening
Market are as follows:
- Absence of proper regulations in developing countries for the use of NAT.
- High capital investments and high maintenance cost of NAT.
- Evolution of substitute technologies.
The Blood
Screening Market is segmented on the lines of its
product, service, technology, end user and regional. Based on product, services
segmentation it coversreagents & kits, enzymes and polymerases, standards
and controls, probes and primers, buffers, nucleotides, and solutions, labeling
and detection reagents, immunosorbents, controls, conjugates, substrates,
sample diluents and wash solutions, instruments, software and services. Based
on technology segmentation it covers nucleic acid test (NAT), enzyme-linked
immunosorbent assay (ELISA), rapid tests, western blot assay, next-generation
sequencing (NGS). Based on end user segmentation it covers blood banks,
hospitals. The Blood Screening Marketon
geographic segmentation covers various regions such as North America, Europe,
Asia Pacific, Latin America, Middle East and Africa. Each geographic market is
further segmented to provide market revenue for select countries such as the
U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
This report
provides:
1) An overview of the global market for Blood Screening Market and related technologies.
2) Analyses of global market trends, with data from 2013, estimates for 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2021.
3) Identifications of new market opportunities and targeted promotional plans for Blood Screening Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
1) An overview of the global market for Blood Screening Market and related technologies.
2) Analyses of global market trends, with data from 2013, estimates for 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2021.
3) Identifications of new market opportunities and targeted promotional plans for Blood Screening Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
REPORT SCOPE:
The scope of the report includes a detailed study of global and regional
markets on Blood
Screening Market with the reasons given for
variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Ortho Clinical Diagnostics, Inc. (U.S.), Becton, Grifols (Spain), Dickinson and Company (U.S.), Roche Diagnostics (Switzerland), Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Siemens Healthineers (Germany), and bioMérieux (France).Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Ortho Clinical Diagnostics, Inc. (U.S.), Becton, Grifols (Spain), Dickinson and Company (U.S.), Roche Diagnostics (Switzerland), Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Siemens Healthineers (Germany), and bioMérieux (France).Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
By Technology
Analysis:
- Nucleic Acid Test (NAT)
- Transcription-mediated Amplification (TMA)
- Real-time Polymerase Chain Reaction (PCR)
- Enzyme-linked Immunosorbent Assay (ELISA)
- By Platform
- Chemiluminescence Immunoassay (CLIA)
- Fluorescence Immunoassay (FIA)
- Colorimetric Immunoassay (CI)
- By Generation
- First Generation
- Second Generation
- Third Generation
- Fourth Generation & Above
- Rapid Tests
- Western Blot Assay
- Next-generation Sequencing (NGS)
By End User
Analysis:
- Blood Banks
- Hospitals
By
Product/Services Analysis:
- Reagents & Kits
- NAT Reagents & Kits
- Enzymes and Polymerases
- Standards and Controls
- Probes and Primers
- Buffers, Nucleotides, and Solutions
- Labeling and Detection Reagents
- ELISA Reagents & Kits
- Immunosorbents
- Controls
- Conjugates
- Substrates
- Sample Diluents and Wash Solutions
- Other Reagents & Kits
- Instruments
- Rental Purchase
- Outright Purchase
- Software and Services
By Regional
Analysis
North America
Europe
Asia-Pacific
Rest of the World
Europe
Asia-Pacific
Rest of the World
Request Sample Report: https://www.marketresearchengine.com/blood-screening-market
Table of Contents
1 INTRODUCTION
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Blood Screening Market, By Technology
7 Blood Screening Market, By Product and Service
8 Blood Screening Market, By End User
9 Blood Screening Market, By Region
10 Competitive Landscape
11 Company Profiles
11.1
Introduction
11.2
Grifols
11.3 F.
Hoffmann-La Roche
11.4
Abbott Laboratories
11.5 Biomérieux
11.6
Bio-Rad Laboratories, Inc.
11.7
Siemens Healthineers (A Subsidiary of Siemens AG)
11.8
Ortho Clinical Diagnostics, Inc.
11.9
Thermo Fisher Scientific, Inc.
11.10
Beckman Coulter (A Subsidiary of Danaher Corporation)
11.11
Becton, Dickinson and Company
Media Contact
Company Name: Market Research Engine
Contact Person: John Bay
Email: john@marketresearchengine.com
Phone: +1-855-984-1862
Country: United States
0 comments:
Post a Comment